Eli Lilly has entered a non-exclusive agreement with digital health firm Rimidi to develop provider-focused tools for delivering personalised diabetes management solutions.

The collaboration is intended to enable effective insulin usage and optimised diabetes management while maintaining normal clinical workflow.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The firms plan to combine Rimidi’s diabetes management software platform with Eli Lilly’s integrated insulin management system that is in the development phase.

Rimidi CEO Lucienne Ide said: “Diabetes management is a collaborative effort between people with diabetes and their healthcare providers.

“With the right support, they can achieve better results together.”

Rimidi’s platform utilises individual characteristics and clinical histories of diabetes patients to detect people who could benefit from a particular management technique.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The integrated system is part of the firm’s Connected Diabetes Ecosystem that is being developed to facilitate effective insulin usage for easy diabetes management.”

The platform runs on top of select electronic medical records systems to provide smooth workflow experience for point of care clinicians.

Lilly’s insulin management system is being developed to combine a connected insulin pen, glucose-sensing technologies and software applications to offer personalised recommendations on insulin dose.

The integrated system is part of the firm’s Connected Diabetes Ecosystem that is being developed to facilitate effective insulin usage for easy diabetes management.

The Ecosystem also includes an automated insulin delivery system that is designed as a hybrid closed-loop platform to leverage connected devices for automated insulin dosing.

Both of the Lilly’s systems are currently undergoing clinical trials and are expected to be commercialised in the coming two to three years.